The main objective of the Nutrition and Metabolic Health Research Group is to integrate nutritional and metabolic knowledge for a better understanding of high prevalent and increasing incidence non-communicable diseases such as obesity, type 2 diabetes, cardiovascular diseases, dementia and cancer. The multidisciplinary group encompasses researchers with expertise in nutrition, lifestyle, and multi-omic (metabolomics-microbiota-transcriptomics) research, strong experience in epidemiological, clinical and pharmacological studies, allowing the progress in the knowledge of these diseases with an holistic and an integrative vision, to better identify biomarkers and target molecules useful for the design of preventive and therapeutic strategies in the field of personalized medicine.
Dra. Mònica Bulló Bonet
NuMeH is a multidisciplinary research group with solid experience in using epidemiological, clinical and pre-clinical approaches to nutrition and lifestyle interactions with chronic pathologies of increasing incidence such as cardiometabolic diseases, cancer, Alzheimer’s diseases and other neurodegenerative diseases and neurotoxicity syndromes. With a strategy clearly focused in the ODS3 identified by the UN in the agenda 2030, the group works in the integration of molecular, clinical, nutritional and environmental data with the aim of improving the prevention, diagnosis and treatment of these diseases. The identification of molecular mechanisms, peripheral biomarkers and potential therapeutic targets, with the integration of the new omic sciences as a central axis in which the group works, is a key tool to advance the innovation and technology transfer and respond to the most important health’s challenges of the current and future society.
A comprehensive life-style and multi-omics integrative approach to study metabolic processes related to cognitive function, cognitive decline and progression to dementia. Fondo de Investigación Sanitaria. Instituto de Salud Carlos III. PI22/01139. 2023-2025. IP: M Bulló
Untangling the link between Insulin Resistance and AD through Metabolomics. Alzheimer Association (USA). ARG-NTF-22-924702.2022-2024. IP: M Bulló. Co-IP: C Papandreou
Role of circulating micro-RNAs as potential biomarkers and therapeutic targets of insulin resistance and Alzheimer’s disease. Instituto de Salud Carlos III-Proyectos colaborativos centrales y de investigación traslacional CIBERned. Coordinador: JL Cantero. IP. M Bulló. 2022-2024
Effects of almond consumption on innate myeloid and lymphoid cells composition and activity. Almond Board of California (USA). 2021-2023. IP. M Bulló
Metabolomic profiles in blood and urine as predictors of response to immunotherapy in lung cancer patients. Fondo de Investigación Sanitaria. Instituto de Salud Carlos III. PI20/01094.2021-2023. IP: C Papandreou
Dietary modulation of miRNAs linking type 2 diabetes and Alzheimer disease: Toward a precision health approach. Fondo de Investigación Sanitaria. Instituto de Salud Carlos III. PI19/00854. 2020-2022 IP: M Bulló
Prevention and Remediation of Insulin Multimorbidity in Europe (PRIME). European Commission. H2020-SC1-BHC-2018-2020. 2025. Coordinador: B Franke. IP. M Bulló
Efecto de la dieta mediterránea sobre los cambios en la composición y la funcionalidad de la microbiota intestinal. Instituto DANONE. 2018-2020. IP: M Bulló
Mental health, nutrition and cognition: follow-up study of the Impact of an Intervention in Mediterranean diet and promotion of physical activity in elderly people with overweight and obesity. Association of a virtual facilitator of the intervention. ERIS – Generalitat de Catalunya, PERIS – Pla estratègic de recerca i innovació en salut. 2018-2021. Coordinador F Fernández-Aranda. IP: M Bulló
Efecto de una dieta basada en alimentos saludables o dieta mediterránea sobre los cambios en la composición y la funcionalidad de la microbiota fecal y su relación con la mejoría metabòlica (METADIET). Fondo de Investigación Sanitaria. Instituto de Salud Carlos III. PI/00516. 2017-2019. Ip. M Bulló
Dispositivo muestreador de micro y nanopartículas en ecosistemas acuáticos y sistema de captación asociado al mismo. Patent: U202031396. R Carafa, J Folch, J Sierra, N Expósito
Validation of protoypes of microplastics sensors and marine pollution measures. DARP – Department of Agriculture, Livestock and Fisheries of the Generalitat de Catalunya Call: Aid from the European Maritime and Fisheries Fund. ARP163/21/000141. 2021. IP: J Folch
Scientific and Medical advice on the approval/renewal of drug marketing authorisations. Laboratorios ERN. T20018S. 2020. IP: FX Sureda
Fanelli G, Mota NR, Salas-Salvadó J, Bulló M, Fernandez-Aranda F, Camacho-Barcia L, Testa G, Jiménez-Murcia S, Bertaina-Anglade V, Franke B, Poelmans G, van Gils V, Jansen WJ, Vos SJB, Wimberley T, Dalsgaard S, Barta C, Serretti A, Fabbri C, Bralten J.
Sanchez-Gimenez R, Peiró ÓM, Bonet G, Carrasquer A, Fragkiadakis GA, Bulló M, Papandreou C, Bardaji A.
Olloquequi J, Cano A, Sanchez-López E, Carrasco M, Verdaguer E, Fortuna A, Folch J, Bulló M, Auladell C, Camins A, Ettcheto M.
Sanchez-Gimenez R, Ahmed-Khodja W, Molina Y, Peiró OM, Bonet G, Carrasquer A, Fragkiadakis GA, Bulló M, Bardaji A, Papandreou C.
Atzeni A, Bastiaanssen TFS, Cryan JF, Tinahones FJ, Vioque J, Corella D, Fitó M, Vidal J, Moreno-Indias I, Gómez-Pérez AM, Torres-Collado L, Coltell O, Castañer O, Bulló M, Salas-Salvadó J.
Busquets O, Espinosa-Jiménez T, Ettcheto M, Olloquequi J, Bulló M, Carro E, Cantero JL, Casadesús G, Folch J, Verdaguer E, Auladell C, Camins A.
Espinosa-Jiménez T, Busquets O, Cano A, Sánchez-López E, Verdaguer E, Parcerisas A, Olloquequi J, Auladell C, Folch J, Wahli W, Vázquez-Carrera M, Camins A, Ettcheto M.
Cañueto D, Salek RM, Bulló M, Correig X, Cañellas N.
Camacho-Barcia L, García-Gavilán J, Martínez-González MÁ, Fernández-Aranda F, Galié S, Corella D, Cuenca-Royo A, Romaguera D, Vioque J, Alonso-Gómez ÁM, Wärnberg J, Martínez JA, Serra-Majem L, Estruch R, Bernal-López MR, Lapetra J, Pintó X, Tur JA, Garcia-Rios A, Bueno-Cavanillas A, Delgado-Rodríguez M, Matía-Martín P, Daimiel L, Martín-Sánchez V, Vidal J, Vázquez C, Ros E, Canela MR, Sorlí JV, de la Torre R, Konieczna J, Oncina-Cánovas A, Tojal-Sierra L, Pérez-López J, Abete I, Sánchez-Villegas A, Casas R, Muñoz-Garach A, Santos-Lozano JM, Bouzas C, Razquin C, Martínez-Lacruz R, Castañer O, Yañez AM, Valls-Enguix R, Belló-Mora MC, Basterra-Gortari J, Basora J, Salas-Salvadó J, Bulló M.
Olloquequi J, Ettcheto M, Cano A, Sanchez-López E, Carrasco M, Espinosa T, Beas-Zarate C, Gudiño-Cabrera G, Ureña-Guerrero ME, Verdaguer E, Folch J, Auladell C, Camins A.
Testa G, Mora-Maltas B, Camacho-Barcia L, Granero R, Lucas I, Agüera Z, Jiménez-Murcia S, Baños R, Bertaina-Anglade V, Botella C, Bulló M, Casanueva FF, Dalsgaard S, Fernández-Real JM, Franke B, Frühbeck G, Fitó M, Gómez-Martínez C, Pintó X, Poelmans G, Tinahones FJ, Torre R, Salas-Salvadó J, Serra-Majem L, Vos S, Wimberley T, Fernández-Aranda F.
Galié S, Papandreou C, Arcelin P, Garcia D, Palau-Galindo A, Gutiérrez-Tordera L, Folch À, Bulló M.
Papandreou C, Harrold JA, Hansen TT, Halford JCG, Sjödin A, Bulló M.
Dra Mònica Bulló: monica.bullo@urv.cat
Facultat de Medicina i Ciències de la Salut, URV
C/ Sant Llorenç, 21 · 43201 Reus
Responsible: Dra. Rosa Solà Alberich
Responsible: Dra. Teresa Auguet Quintillà
Responsible: Dra. Montse Pinent Armengol
Responsible: Dr. Alfredo Bardají